Multiple sclerosis: Critical review of the evidence for each question

Evidence-Based Neurology: Management of Neurological Disorders

Volumn , Issue , 2007, Pages 221-233

  Filippini, Graziella ^a   Ebers, George ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890997466     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988350.ch21     Document Type: Chapter

References (47)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31.
2. Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J. Neurol. 2005; 252: 396-402.
3. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch. Ophthalmol. 2003; 121: 944-9.
4. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 2002; 346: 158-64.
5. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for clinical protocol research. Ann. Neurol. 1983; 13: 227-31.
6. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001; 50: 121-7.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
8. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 1989; 8: 431-40.
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
10. Pittock SJ, Mayr WT, McClelland RL, Noseworthy JH, Rodriguez M. Clinical implications of benign MS: a 20 year population-based follow up study. Ann. Neurol. 2004; 56: 303-6.
11. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL. Studies on the natural history of multiple sclerosis, 8: early prognostic features of the later course of the illness. J. Chronic. Dis. 1977; 30: 819-30.
12. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989; 112: 133-46.
13. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 122: 1941-50.
14. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 9. Observations on the progressive phase of the disease. Brain 2006; 129: 584-94.
15. Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 2039-44.
16. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J. Neurol. 2000; 247: 435-42.
17. Goodin DS, Frohman EM, Garmany Jr GP, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78.
18. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapies of multiple sclerosis. J. Neurol. 2004; 251: 1329-39.
19. Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, et al. EFNS Task Force on Treatment of Multiple Sclerosis Relapses. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur. J. Neurol. 2005; 12: 939-46.
20. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis (Cochrane Review). The Cochrane Library, 2003, 2, Oxford: Update Software: CD001331.
21. Jacobs LD, Beck RW, Simon JH, et al. CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 2000; 343: 898-904.
22. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001; 357: 1576-82.
23. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann. Neurol. 2002; 51: 481-90.
24. Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sandberg-Wollheim M, et al. Paris Workshop Group. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult. Scler. 2002; 8: 19-23.
25. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D’Amico R, Rice GP. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361: 545-52. (Cochrane Review).
26. Martinelli Boneschi F, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebocontrolled clinical trials. Mult. Scler. 2003; 9: 349-55.
27. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. (Cochrane Review). The Cochrane Library, 2004, 1, Oxford: Update Software: CD004678.
28. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis [letter]. Lancet 1997; 350: 261.
29. Sudlow CLM, Counsell CE. Problems with UK government risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003; 326: 388-92.
30. Casetta I, Iuliano G. Azathioprine treatment for multiple sclerosis (Protocol). The Cochrane Database of Sys. Rev. 2003; 1: CD003982. DOI: 10.1002/14651858.CD003982.
31. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988; ii: 179-83.
32. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 1332-8.
33. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. (Cochrane Review). The Cochrane Library, 2005; 4, Oxford: Update Software: CD002127.
34. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.
35. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 1997; 62:112-8.
36. Millefiorini E, Gasperini C, Pozzilli C, D’Andrea F, Bastianello S, Trojano M, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. 1997; 244: 153-9.
37. van de Wyngaert FA, Beguin C, D’Hooghe MB, Dooms G, Lissoir F, Carton H, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg. 2001; 101: 210-6.
38. Association of British Neurologists. Guidelines for the use of intravenous immunoglobulin in neurological disease. March 2002.
39. Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst. Rev. 2003; 4: CD002936. Review.
40. European Study Group on Interferon -1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon -1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
41. The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-95.
42. SPECTRIMS Study Group, Hughes RAC. Randomized controlled trial of interferon beta-1a in secondary progressive MS. Clinical Results. Neurology 2001; 56: 1496-504.
43. Cohen JA, Cutter GR, Fisher JS, Goodman AD, Heidenreich FR, et al. Benefit of IFN beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-86.
44. Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr K-M. The Nordic SPMS Study Group. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 2004; 75: 706-10.
45. Liu C, Blumhardt D. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J. Neurol. Neurosurg. Psychiatr. 2000; 68: 450-7.
46. Pittock SJ, Weinshenker BG, Noseworthy JH, Lucchinetti CF, Keegan M, Wingerchuk DM, et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol. 2006; 63: 611-4.
47. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol. 2006; 63: 614-9.